CNS Pharmaceuticals shareholders approve 4x increase in authorized shares, reverse split authorization

CNS Pharmaceuticals, Inc.

Authorized common shares increased from 75M to 300M; 3.5M shares added to 2020 Equity Plan (total 4,345,800).
Board authorized to effect reverse stock split from 1:2 to 1:50 within one year.
Stockholders approved repricing of 3.756M warrants from $1.28 to $0.30 and extension to Feb 2029.
All six director nominees elected; board committees appointed (Audit, Comp, Nominating/Governance).
Ratified MaloneBailey LLP as independent auditor for FY 2024.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.98

CNS Pharmaceuticals, Inc.: On May 2, 2024, the Company filed a Certificate of Amendment to its Amended and Restated Articles of Incorporation to increase authorized shares of common stock from 75,000,000 to 300,000,000, as approved by stockholders at the Annual Meeting on April 30, 2024 (effective 2024-05-02).

Change: charter amendment
Effective: 2024-05-02

Exact text from the filing

On May 2, 2024, the Company filed a Certificate of Amendment to its Amended and Restated Articles of Incorporation (the “Amendment”) with the Secretary of State of the State of Nevada to increase the number of the Company’s authorized shares of common stock from 75,000,000 shares to 300,000,000 shares.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.7

CNS Pharmaceuticals, Inc. shareholders approved Approval of amendments to the Company's 2020 Equity Plan, including an increase in the number of shares of common stock authorized for issuance by 3,500,000 shares.

Proposal: equity plan
Outcome: passed

Exact text from the filing

CNS Pharmaceuticals, Inc. (the “Company”) held its scheduled 2024 Annual Meeting of Stockholders (the “Annual Meeting”) at which the Company’s stockholders approved amendments to the Company's 2020 Equity Plan (the “2020 Plan”) including an increase in the number of shares of common stock, par value $0.001 per share, authorized for issuance under the 2020 Plan by 3,500,000 shares.

View on SEC.gov

42 governance changes filed in the last 30 days. Browse all governance changes →

CNS Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-24-002961

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.